{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 102 of 122', 'Positive OLFC', 'Treatment of subjects with symptoms: Treat subjects with any symptoms elicited by the', 'OLFC per the accepted medical practices at the study site. Record all treatments', \"administered for allergic reactions during an OLFC in the subject's source documents and on\", 'case report forms.', 'Following the initial treatment:', '1. Repeat treatments as needed, at the discretion of the physician.', '2. Monitor vital signs (blood pressure, heart rate, temperature) at least every 15 minutes', 'until symptoms resolve, then 30 and 60 minutes after symptoms resolve, then hourly until', 'releasing the subject.', '3. Monitor pulse oximetry if laryngeal, lower respiratory, or cardiovascular symptoms are', 'present.', '4. Follow these guidelines for further observation based on symptom severity:', 'For severe symptoms, observe the subject for a minimum of 3 hours after the', 'symptoms resolve, either at the study site or an emergency facility, as appropriate.', 'Consider extended overnight observation if symptoms are protracted.', 'For moderate symptoms, observe the subject for a minimum of 2 hours after the', 'symptoms resolve, and longer if necessary.', 'For mild symptoms, observe the subject for a minimum of 2 hours or for 1 hour after', 'the symptoms resolve, whichever is longer.', '5. Do not release a subject with symptoms or with abnormal vital signs if changed from', 'baseline. As appropriate, arrange for continued observation at the study site, an', 'emergency facility, or an extended-stay (inpatient) unit. Record signs and symptoms that', \"changed from baseline in the subject's source documents.\", '6. Generally, if the emergence of allergy symptoms halts the OLFC, consider the last', 'symptom-eliciting dose to be \"not tolerated\" and record it as such on the case report', 'form.', 'Exceptions to this guidance may include situations where the OLFC is halted (eg, due', 'to anxiety or refusal to continue) and symptoms are mild and not considered to be', 'dose-limiting.', 'POST-OLFC INSTRUCTIONS AND FOLLOW-UP', 'Before releasing the subject, study site staff should inform the subject and parent/caregiver of', 'the following:', '1. The subject may resume eating and drinking without restrictions 30 minutes after the last', 'OLFC dose is administered. Subjects who tolerate at least 300 mg of peanut protein at', 'the OLFC will resume study treatment (AR101 or standard of care alone) the day after', 'the OLFC.', '2. Review the possibility of delayed allergy symptoms and provide guidance on how to', 'recognize anaphylaxis.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 103 of 122', '3. Verify that they possess an epinephrine auto-injector with an appropriate dose and expiry', 'date before release, and review the instructions for administration of injectable', 'epinephrine.', '4. Provide study site staff contact information and procedures for after-hours emergencies.', '5. Instruct that the subject is to continue to avoid eating peanuts and foods known to contain', 'peanuts.', '6. Schedule a follow-up study appointment according to the protocol.', '7. Telephone the following day to inquire about post-OLFC adverse events, and assist', 'accordingly.', 'REFERENCE', 'Sampson HA, Gerth van Wijk R, Bindslev-Jensen C, Sicherer S, Teuber SS, Burks AW, et al. Standardizing', 'double-blind, placebo-controlled oral food challenges: American Academy of Allergy, Asthma &', 'Immunology-European Academy of Allergy and Clinical Immunology PRACTALL consensus report. J Allergy', 'Clin Immunol. 2012;130(6):1260-74.']\n\n###\n\n", "completion": "END"}